

## IACC 2023 Case-based discussion (CBD) scenario

<b>Specialty:</b>	<b>Cancer Genomics</b>
-------------------	------------------------

### CBD Scenario

<b>CBD Scenario Title</b>	Lymphocytosis and integrated reporting									
<b>CBD Scenario Aim</b>	To determine the trainee's understanding of the diagnosis of B CLL, the appropriate testing pathways for a patient with B CLL and the importance of an integrated report									
<b>CBD Focus</b> (please provide the codes of the module(s) this scenario addresses)	Core module (professional practice) SCC110			Essential module (Haematological Malignancies 1) SLS429			Essential module (Haematological Malignancies 2) SLS431			
<b>GSP Domains covered</b> (enter X to indicate all that apply)	<b>GSP 1</b>		<b>GSP 2</b>	X	<b>GSP 3</b>	X	<b>GSP 4</b>		<b>GSP 5</b>	
<b>CBD Scenario description</b>	<p>What are the diagnostic criteria for diagnosing B CLL?</p> <p>Discuss the key results which are included in an integrated haematological report, with examples.</p>									
<b>CBD Scenario model answer/ assessor guidance</b>  Detailed guidance that will be available for the assessors. Include guidance on what kinds of behaviours, actions, comments should secure a pass. What should the assessor expect to see? Assessors will be asked to plan questions in advance including links to trainee's IACC submission.	<p><b>Diagnostic criteria</b></p> <ul style="list-style-type: none"> <li>• Small, mature-appearing lymphocytes with a narrow border of cytoplasm and a dense nucleus lacking discernible nucleoli and having partially aggregated/condensed chromatin.</li> <li>• Presence of <math>5 &gt; 10^9</math> /l monoclonal B lymphocytes in the peripheral blood.</li> <li>• Demonstrating B cell clonality by light chain restriction using flow cytometry.</li> <li>• CD23+, CD5+, CD19+, slgwk, CD200+, CD43+, CD79bwk+, CD20wk+, CD22+</li> <li>• Matutes score 4/5 = B CLL (&gt;92% of B CLL cases)</li> </ul>									

	<p><b>Integrated report</b></p> <ul style="list-style-type: none"> <li>• Patient details, specimen type/date of sample</li> <li>• SIHMDS episode number</li> <li>• Full blood count</li> <li>• Morphology</li> <li>• Immunophenotyping</li> <li>• Cytogenetics</li> </ul> <p>FISH/NGS copy number: del(11q) (ATM), del(13q) (RB1), add(12), del(17p) (TP53)</p> <ul style="list-style-type: none"> <li>• Mutation analysis</li> </ul> <p>SHM SHM – IGVH mutation - germline vs hypermutation</p> <p>NGS for other genes prognostic in CLL e.g., NOTCH1, SF3B1, ATM</p> <ul style="list-style-type: none"> <li>• Conclusion</li> <li>• WHO classification</li> <li>• MDT review</li> <li>• Dual sign off</li> </ul>
<p><b>Trainee instructions</b></p> <p>Please include any specific information to be provided to the trainee as part of the CBD scenario</p>	

## Criteria being assessed by this CBD scenario

Aspect	Please indicate if this criterion is being assessed
1. Understands the clinical context of the scenario, including priority setting and testing strategies	X
2. Understands scientific principles of scenario	
3. Can discuss the relevant procedures involved in the scenario and associated health and safety issues	X
4. Understands and applies the appropriate test validation, IQC, EQA, relevant professional/clinical guidelines	
5. Understands and applies associated IT/bioinformatics and other appropriate resources	

6. Is able to interpret and report patient results and provide appropriate clinical advice	
7. Can discuss the significance of patient results within the clinical context of the referral	X
8. Understands the ethical, legal and social implications of the scenario	
9. Is aware of the importance of audit and can use this tool effectively	
10. Output meets accepted laboratory/professional standards	
11. Demonstrates awareness of the limits of responsibility and when to seek advice	
12. Consideration of patient/professionalism	
13. Overall ability to perform	